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CObjectives: Many clinical treatments have multiple effects that can
only be effectively captured on multiple outcome scales. It might be
important to understand how these outcomes are correlated to evalu-
ate the effectiveness and cost-effectiveness of treatments in decision
models. Methods: The probabilities are estimated that both, one, or
neither outcome occurs, given estimates of themarginal probability for
each outcome and information about the correlation between them.
Methods are shown for different measures of association. Lower and
upper bounds for the correlation coefficient are calculated for given
values of themarginal probabilities. The approach is illustrated using a
simplified decisionmodel based on a recent evaluation of adalimumab,
a biologic drug for psoriatic arthritis. Results: Assuming the outcomes O
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doi:10.1016/j.jval.2011.04.007re positively correlated, the probability of both a skin and arthritis
esponse after adalimumab was estimated to be 0.387 (95% confidence
nterval 0.210–0.570). The incremental cost-effectiveness ratio (ICER) of
dalimumab versus no biologic is £18,500 per quality-adjusted life-year
QALY). The ICER increases to £19,500 per QALY if the responses are
ndependent. Conclusion: Estimates of ICERs can be sensitive to as-
umptions about how multiple outcomes are correlated. These as-
umptions should be explored in univariate and probabilistic sensitiv-
ty analyses.
eywords: correlation, decision model, meta-analysis, outcome.
opyright © 2011, International Society for Pharmacoeconomics and
utcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Many clinical treatments have multiple effects that can only be
effectively captured on multiple outcome scales. For example, bi-
ologic treatments for psoriatic arthritis aim both to alleviate
symptoms of psoriasis and to slow progression of joint disease.
Adjuvant chemotherapy may aim to prevent recurrence of cancer
but have side effects. Varicose vein surgery aims to occlude the
great saphenous vein and improve the appearance or symptoms
of surface varicosities. It might be important to understand how
these outcomes are correlated to evaluate the overall effective-
ness and cost-effectiveness of these treatments. Further clinical
interventions, costs, and health-related quality of lifemay depend
on whether patients have neither, one, or both outcomes. This
article is concerned with estimating the contingent probabilities
(the probability of both, one, or neither outcome occurring) for two
outcomes, where each ismeasured on a dichotomous scale. These
data can be summarized by a 2  2 table of outcomes for each
reatment, as in Table 1. It is anticipated that these data will be
sed as parameter inputs in a decision model. Although two bi-
ary outcomes are a special case, it is one that is encountered
uite frequently in health technology appraisal (HTA). For exam-
le, the responses to biologic treatment for psoriatic arthritis are
ommonly measured using the Psoriatic Arthritis Response Crite-
ia (PsARC) for joint disease and the Psoriasis Area Severity Index
PASI) 75 for skin disease [1].
* Address correspondence to: David Epstein, Centre for Health
Kingdom.
E-mail: david.epstein@york.ac.uk.
1098-3015/$36.00 – see front matter Copyright © 2011, Internation
Published by Elsevier Inc.Syntheses of clinical effectiveness are usually performed as a
nivariate meta-analysis on each outcome. Statistical methods
or the meta-analysis of multiple outcomes do exist and may give
mproved precision in terms of univariate or marginal inferences
hen complete data on both outcomes are available, including the
orrelation between the treatment effects, which is rarely re-
orted in clinical studies [2–4]. But the key interest from meta-
nalyses of multiple outcomes is usually marginal treatment ef-
ects and their associated uncertainty (perhaps with a joint
onfidence interval [CI]), rather than making inferences about the
ontingent probabilities [2]. Perhaps for lack of suitable data, lack
f appropriate analytical methods, or, simply for convenience,
ome decision models omit potentially important outcomes or
orrelations, for example, ignoring response to the skin condition
n psoriatic arthritis [5] or assuming multiple outcomes are inde-
endent [6].
The aim of this article is to demonstrate a relatively simple and
ragmatic method for estimating the expected contingent proba-
ilities of outcomes (the internal cell probabilities of a 2  2 table)
hen only the marginal probabilities for each outcome in each
reatment are available, together with some measure of the asso-
iation between the outcomes. It might be noted that these con-
ingent probabilities could be estimated relatively straightfor-
ardly if individual patient data (IPD) were available from every
tudy [7]. In the absence of IPD, the expected marginal probabili-
ies for each outcome in each treatment (together with estimates
omics, University of York, Heslington, York YO10 5DD, United
ciety for Pharmacoeconomics and Outcomes Research (ISPOR).
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794 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 7 9 3 – 7 9 9of uncertainty)might be obtained fromany appropriate source, for
example, a single study or estimated from univariate meta-anal-
yses from several randomized, controlled trials (RCTs). An esti-
mate of the correlation between these two outcomes in each treat-
ment is also required. Ideally, these correlation coefficients would
be reported by randomized clinical studies, but this is rarely the
case, and the estimate might be obtained from other sources or
expert opinion.
There are several alternative measures of association for 2  2
ables, for example, the tetrachoric, the phi coefficient, Yule’s Q, and
ule’s Y, among others. This article discusses the properties of these
oefficients and discusses how eachmight be used to deal with cor-
elatedoutcomes in adecisionmodel. Theapproaches are illustrated
sing an example from a recent health technology appraisal [8].
Themethod used in this article is a simple application from an
xtensive literature knownas ecological inference. The aimof eco-
ogical inference is to recover the internal cell counts or fractions
f 2  2 (or, in general, r  c) tables when the primary data report
nly the marginal frequencies, with at most only a few previous
ata to inform the correlation coefficient. This problem is akin to
aking individual level inferences fromecological data. Ecological
nference methods have been applied to many problems in the
ocial sciences and epidemiology; Wakefield [9] provides a com-
rehensive review. This literature, however, appears not to be
ell-known among practitioners of HTA, perhaps because its ap-
lication is at the interface between meta-analysis and decision
nalysis. As these functions are often undertaken by different
echnical specialists, possibly neither has recognized its potential.
Methods
Measures of association
The purpose of this article is to establish a method for recovering
the internal cell probabilities of a 2  2 table given aggregate data
on themarginal probabilities and some estimate of the association
between the variables. If there are two binary outcomes (X and Y),
Table 1 – Bivariate proportions table for binary
variables.
Variable Y
Value 1 Value 2 Total
Value 1 a b Px
Variable X Value 2 c d Qx
Total Py Qy 1
Table 2 – Frequencies (and fraction) of participants with ar
controlled trial at 12 weeks for patients in the adalimumab
least 3% body skin area affected by psoriasis at baseline [1
Adalimumab
Skin response
Y  1
No skin respo
Y  0
Arthritis response, X  1 29 (0.45) 14 (0.21)
No arthritis response, X  0 5 (0.08) 18 (0.27)
Total 34 (0.53) 32 (0.47)
Arthritis response measured using the Psoriatic Arthritis Response
Severity Index 75. The estimate of the odds ratio x comparing the m
this trial is (0.66/0.34)/(0.25/0.75)  5.8. The estimate of the odds ratio
adalimumab with placebo in this trial is (0.53/0.47)/(0.04/0.96)  27.1.then individuals can be in one of four states: X only, Y only, X and
, or neither. The proportion of individuals in each of the four
tates can be summarized in a 2 2 table for each treatment (Table
). Variable a represents the expected probability that bothX andY
ill occur, d represents the probability that neither X nor Y will
ccur, and b and c represent the probabilities that only X or only Y
ill occur.
For example, Table 2 shows the observed outcomes of an RCT
omparing adalimumab versus placebo for psoriatic arthritis. In
his case, full information was available on the internal cell fre-
uencies as well as the total (or marginal) frequencies of each
utcome [10]. Outcome X is a binary measure of arthritis response
PsARC) and Y is a binary measure of psoriasis response (PASI 75)
1].The marginal probabilities of success at 12 weeks in the inter-
ention (adalimumab) group in the trial are represented as Pr1(x
1)  Px for PsARC and Pr1(y  1)  Py for PASI 75. In this case, the
estimate of Pr1(x  1)  0.21  0.45  0.66 and Pr1(y  1)  0.08 
.45 0.53. Similarly, the estimates of themarginal probabilities of
uccess at 12 weeks in the placebo group are Pr0(x  1)  0.25 for
sARC and Pr0(y  1)  0.04 for PASI 75.
There aremany possible measures of association that could be
sed tomeasure the strength of a relationship between two binary
ariables. Warrens [11] provides an overview. For the purposes of
his article, a suitable coefficient of association for handling binary
utcomes in a decisionmodel should satisfy two essential criteria.
irst, the measure should be defined using the four internal cell
robabilities a, b, c, and d presented in Table 1. This ensures that
alues of a, b, c, and d can be recovered by back-transformation
iven estimates of the expected marginal probabilities and an es-
imate of the association. Second, the coefficient should have zero
alue under statistical independence [12,13]. The following sec-
ions discuss the properties of the phi coefficient, the tetrachoric
oefficient, Yule’s Q, and Yule’s Y and their potential usefulness to
odel correlated outcomes.
The phi coefficient
The Pearson correlation coefficient for outcomes X and Y is de-
ned as the covariance of the variables divided by the product of
heir standard deviations:
 covx,y ⁄xy (1)
If X and Y are binary, the measure is known as the phi coefficient
and can be expressed as (see Appendix 1, found at doi:
10.1016.j.val.2011.04.007) [14]:
 a PxPy ⁄PxPyQxQy (2)
here Px  a  b, Qx  1  Px, Py  a  c, and Qy  1  Py.
is and skin responses in the ADEPT randomized
up (n = 66) and placebo group (n = 69) for patients with at
Placebo
Total Skin response
Y  1
No skin response
Y  0
Total
43 (0.66) 1 (0.01) 17 (0.24) 18 (0.25)
23 (0.34) 2 (0.03) 49 (0.72) 51 (0.75)
n  66 3 (0.04) 66 (0.96) n  69
eria instrument; skin response measured using the Psoriasis Area
l probability of arthritis response after adalimumab with placebo in
r the comparing the marginal probability of psoriasis response afterthrit
gro
0].
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795V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 7 9 3 – 7 9 9The phi coefficient has zero value under statistical indepen-
dence [11–13,15]. From the data in Table 2 in the adalimumab
roup (treatment j 1), the sample estimate of  is r1 0.436. The
standard error is SEr11r12⁄N2 0.112 and the 95%CI is
0.211 to 0.661, P  0.0015 [16]. In the placebo group (treatment j 
), r0  0.035 (95% CI 0.224 to 0.264, P  0.87). The difference
etween r1 and r0 is significant (P  0.01) [16]. There appears to be
a strong association between the responses in the treatment
group and a lack of association in the placebo group.
Estimating contingent probabilities from the marginal
probabilities and the phi coefficient
The previous section reviewed how the phi coefficient is calcu-
lated for two binary outcomes. This section shows how to re-
cover the internal cell values of a 2  2 table (the contingent
probabilities a, b, c, and d) if estimates of the expected marginal
probabilities of each outcome (Px and Py) and the phi correlation
coefficient were available. This is possible because, given the
marginal probabilities, there is only 1 degree of freedom re-
maining, and the value of the correlation coefficient then serves
to determine the 2  2 table of probabilities in full. For example,
Pr1(x  1) might be calculated from an estimate of the odds of
he outcome X in the population with treatment 0 [Pr0(x  1)/
r0(x  0)] combined with an estimate log(x) of the log odds
ratio for outcome X of treatment 1 versus treatment 0. The log
odds ratio represents the incremental effect of treatment 1 ver-
sus treatment 0 on the overall risk of outcome X in the popula-
tion and is assumed to be independent of the correlation j
between outcome X and outcome Y for treatment j  0 or j  1.
It is assumed for now that an estimate rj of the phi coefficient
j) between outcomes X and Y for treatment j is available from
ome source. Given these data, the expected probability that
oth outcomes will occur in the population after treatment j, a
rj(x  1, y  1), can be calculated, conditional on the marginals.
Rearranging Equation 2, given fixed r, Px, and Py:
 rPxPyQxQy PxPy (3)
The expected probabilities b, c, and d of the other contingent
outcomes can then easily be determined.
Although the phi coefficient has the two essential properties
outlined previously, it has the inconvenient property that its
maximum and minimum values are not independent of the
marginal probabilities, that is, the bounds are attenuated [11].
Furthermore, even if one outcome always occurs with the other
then the value of  can be less than 1, and it can be greater than
1 even if the outcomes never occur together (see Appendix 1,
found at doi:10.1016.j.val.2011.04.007).
The phi coefficient is a widely known and used measure of
association in themedical literature. If the phi coefficient has been
reported by one or more clinical studies and is to be used in a
decisionmodel, then these attenuated boundsmust also be incor-
porated in the decision model and corresponding probabilistic
sensitivity analysis. The article demonstrates how to calculate
these logical limits on the magnitude of the phi coefficient, given
the expected marginal probabilities.
Bounds on the phi coefficient
If the row and column totals of a 2  2 table are known, there are
logical bounds on the four cell values within the table [17]. Given
that Px a b, and probabilities take values between 0 and 1, then
he probability of any internal cell can be no greater than the prob-
bility of the row or columnmargin. These inequalities imply that
here are also bounds on the values that the sample estimate r of
he phi coefficient can take that aremore restrictive than1 to1,
or given values of themarginal probabilities for each outcome for
reatment j. The lower limit lj and upper limit uj for r are (see aAppendix 2, found at doi:10.1016.j.val.2011.04.007):
MaxoddsXoddsY; 1 ⁄oddsXoddsY
	r	
MinoddsX ⁄ oddsY;oddsY ⁄ oddsX
where oddsX Px ⁄Qx and oddsY Py ⁄Qy.
(4)
Equation 4 does not tell us how likely it is that themean sample
estimate rj of the phi coefficient lies at the extremes or near the
center of this range. This uncertainty is represented by the CI of rj.
ather, it represents the logical bounds within which the phi co-
fficient must lie if its value is to be consistent with previously
stimated mean values of the marginal probabilities of each out-
ome. Equation 4 shows that the logical range of j will always
cross zero (independence [13]) for all values of the marginal prob-
abilities for any j. This is an example of the ecological fallacy: it is
never possible to rule out independence, negative or positive cor-
relation between two variables from aggregate (marginal) data
alone [9].
The maximum and minimum logical values for a  Prj(x  1,
y 1) and the other internal cell probabilities for treatment j can be
alculated and used in sensitivity analyses. Given values for the
xpected marginal probabilities Prj(x  1) and Prj(y  1), the lower
limit lj and upper limit uj on the correlation coefficient rj can be
calculated from Equation 4 for treatment j. These values can then
be substituted for rj in Equation 3 to calculate the corresponding
pper and lower limits of a  Prj(x  1, y  1) for treatment j,
onditional on the marginal probabilities.
Probabilistic sensitivity analysis
Where the phi coefficient is used to model the dependency be-
tween the outcomes, the bounds for phi depend on the expected
marginal probabilities. These parameters, however, are sample
estimates, not known values, and this uncertainty is reflected in
the model through Monte Carlo (MC) simulations. The MC algo-
rithm calculates the bounds for phi in each simulation and checks
that the sampled value for the phi coefficient is within these
bounds. In each MC iteration, a sample value rj of the phi coeffi-
cient (assuming a normal distribution) and sample values of the
marginal probabilities of each outcome in treatment j are selected.
The bounds [lj, uj ] for the phi coefficient are then calculated, given
he marginal probabilities. If the sampled rj is outside [lj,uj ], then
ts value is replaced by the bound. This approach to model a vari-
ble whose distribution has finite bounds is analogous to one
sed by Warn et al. [18]. Appendix 3, found at doi:10.1016/
.val.2011.04.007, provides a more formal description of the MC
lgorithm.
Other measures of association
Thephi coefficient iswell-knownbut is only onepossiblemeasure of
association that could be used. Table 3 compares the properties of
some alternative measures. This section discusses the tetrachoric,
Yule’s Q, and Yule’s Y. The tetrachoric correlation assumes the ob-
served 2  2 table is a dichotomization of an underlying bivariate
normal distribution [11,15]. However, even if this assumption were
considered valid in a given data set, the tetrachoric coefficient is es-
timated by maximum likelihood methods [15]. Its expected value
cannot be expressed as a function of probabilities a, b, c, and d (as can
he other measures discussed in this article). Therefore, given esti-
ates of the expected marginal probabilities and an estimate of the
etrachoric correlation, it is not possible to back-transform to recover
hese internal cell probabilities. Consequently, this measure is not
seful for the purposes of constructing a decision model using the
pproach described in this article and is not discussed further.
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Q ad bc ⁄ ad bc (5)
Like the phi coefficient, its value is zero ifX and Y are statistically
independent. Unlike the phi coefficient, the maximum and mini-
mum values of Yule’s Q are independent of the marginal probabili-
ties, that is, they are always unity and negative unity, respectively.
Given fixedmarginals, however, Yule’s Q is a quadratic function of a.
This can be seen by substituting b Px a, c Py a, and d 1 Px
 Py a in Equation 5. This implies that there may be two solutions
hat solve forprobabilitya, givenfixedvaluesofPx, Pyandanestimate
r of Yule’s Q. The two solutions for a are
a BB2 4AC  ⁄ 2Aor a BB2 4AC ⁄ 2A
(6)
here A  2r; B  1  r  2rPx  2rPy; C  PxPy  rPxPy.
Only oneof these solutions is correct (i.e., gives estimates of prob-
abilities a, b, c, and d between 0 and 1); the correct solution is the one
hat satisfies the inequalities 0	 a	 Px and 0	 a	 Py. Yule’s Y (see
Table 3 for definition) also gives a tractable, if even more compli-
cated, solution for a. Therefore, Yule’s Q and Yule’s Y appear to be
appropriate measures of association between clinical outcomes and
either could in principle be incorporated in a decision model. Con-
ceptually, Yule’s Q and Yule’s Y are considered approximations to
the tetrachoric coefficient, whereas the phi coefficient is what the
Pearson coefficient becomeswhen the variables are truly binary [11].
The fact that the bounds of Yule’s Q and Yule’s Y are independent
of themarginal probabilitiesmight be considered an advantage over
the phi coefficient; however, Yule’s Q and Yule’s Y seem to be rarely
used in the clinical trials literature.
Illustrative example of a decision model
A simple decision model was constructed to illustrate the impact
that different assumptions about correlation between outcomes
could have on estimates of costs and quality-adjusted life-years
(QALYs), and the potential bias associated with assuming the out-
comes are independent. The model compares the cost-effective-
ness of adalimumab (a biologic therapy) versus no biologic therapy
for psoriatic arthritis [8]. Themodel structure is shown in Figure 1.
The patient is assessed after 12 weeks of biologic therapy to
measure the response to skin disease (using the PASI 75) and
arthritis (using the PsARC). Therefore, at 12 weeks, the patient
can have responded to both, one, or neither of these compo-
nents. Current guidelines recommend that biologic therapy is
discontinued in patients whose arthritis fails to respond by this
time [1]. The model can consider alternative rules, such as dis-
continuing biologic therapy only in patients who fail to respond
to both PsARC and PASI 75 [19]. Illustrative assumptions are
made about the lifetime discounted costs (relative to no biologic
therapy) and QALYs (relative to no biologic therapy) associated
with each outcome at 12 weeks (Table 4). This simplified model
is not intended to support any real-life decision concerning
these therapies. A complete version of themodel is presented in
Rodgers et al. [8].
Two RCTs compared adalimumab to placebo for skin re-
sponse and arthritis response [10,20]. Univariate meta-analyses
were used to estimate the relative treatment effects and mar-
ginal probabilities of each outcome for the two treatments [8]
(Table 5). Contingent data (Table 2) were only available from one
of these two trials [10], and it was assumed in the base-case
model that the phi correlation coefficient was 0.436 (95% CI
0.211–0.661) for adalimumab and that outcomes were indepen-
dent for no biologic therapy.
T M O p T Y Y C * †
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Deterministic analyses
Given the estimates from the literature of the marginal probabili-
ties for each outcome and a positive association between the out-
comes with adalimumab (a phi coefficient of 0.436) (Table 5), the
predicted probability (calculated by Equation 3) of a response to
both skin and arthritis is 0.387 with adalimumab and 0.011 for no
biologic therapy (Table 6). The corresponding incremental lifetime
mean total cost per patient with adalimumab versus no biologic is
£25,236, the incremental QALYs are 1.368, and the incremental
cost-effectiveness ratio (ICER) is £18,453 per QALY (Table 6). Iden-
tical results would be obtained in the decision model if the mea-
Fig. 1 – Structure of the illustrative model. Costs and
quality-adjusted life-years of each outcome are shown
relative to those of no biologic therapy. Cost, lifetime
health service costs arising from each outcome at 12
weeks; PASI, Psoriasis Area Severity Index score,
measured at 12 weeks; PsARC, Psoriatic Arthritis Response
Criteria, measured at 12 weeks; QALY, Lifetime quality-
adjusted life-years arising from each outcome at 12 weeks.
Table 4 – Incremental lifetime cost and QALY associated w
compared to never starting biologic therapy.
State at 12 wk Incremental cost, £
Patient responds to both skin and
arthritis and is maintained on biologic
therapy
40,000
Patient responds to arthritis only and is
maintained on biologic therapy
44,000
Patient responds to skin only and is
withdrawn from biologic therapy
2317
Patient does not respond to either
outcome and is withdrawn from
biologic therapy
2317
(Sensitivity analysis) Patient responds to
skin only and is maintained on
biologic therapy
50,000The values are illustrative only.sure of association between outcomes for adalimumab were
Yule’s Q with a mean value of 0.749.
Univariate sensitivity analyses
If it were assumed that the responses were independent for
adalimumab and the marginal probabilities of each outcome
were unchanged, then the predicted probability of a response
with adalimumab to both skin and arthritis is 0.280 (Table 6).
The incremental cost increases to £25,665 and the incremental
QALYs decrease to 1.310, and the ICER increases to £19,532 per
QALY (Table 6).
Given the marginal probabilities, the lower and upper bounds
on the phi correlation between the outcomes (calculated by Equa-
tion 4) are 0.878 	 r1 	 0.801 for adalimumab and 0.124 	 r0 	
0.373 for placebo.
Given the expected values of the marginal probabilities, the
lower limit of the phi coefficient would be 0.878 and the cor-
responding probability of both a skin and arthritis response at
12 weeks with adalimumab would be 0.064 (Table 6). In this
case, the ICER would be £21,997 per QALY (Table 6). The upper
limit of the phi coefficient would be 0.801, and the correspond-
ing probability of both responses at 12 weeks with adalimumab
would be 0.477. The ICER in this case would be £17,612 per QALY.
The model structure allows alternative continuation rules for
biologic therapy to be examined. Patients could be continued on
biologic therapy if they respond to either skin or arthritis at 12
weeks [19]. In this case, biologic therapy would be more effective
on average but more expensive, and the ICER (assuming a corre-
lation of 0.436 between the outcomes after 12 weeks of adali-
mumab) is £20,857 per QALY (Table 6). Varying the correlation
coefficient in this scenario has a greater impact on the ICER than
the base-case continuation rule. If the outcomes were indepen-
dent in this scenario, then the ICER would increase to £24,820 per
QALY.
Probabilistic sensitivity analysis
Probabilistic sensitivity analysis using the base-case parameters
(Tables 2 and 3) estimated themean (95% CI) incremental cost was
£25,148 (15002–33342) and incremental QALY was 1.358 (0.801–
1.810). The probability that adalimumab was cost-effective versus
no biologic was 0.95 at a threshold of £20,000 per QALY and 1.00 at
a threshold of £30,000 per QALY.
ach model state after 12 weeks with adalimumab
Incremental QALY Comment
2.5 Mean lifetime cost of biologic therapy
(£54,000) less health service cost
savings of £14,000
2.0 Mean lifetime cost of biologic therapy
(£54,000) less health service cost
savings of £10,000
0 Cost of biologic therapy for 12 weeks
0 Cost of biologic therapy for 12 weeks
0.5 Mean lifetime cost of biologic therapy
(£54,000) less health service cost
savings of £4000ith e
k
m
798 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 7 9 3 – 7 9 9Conclusion
This article has shown a method for predicting the contingent
probabilities of both, one, or neither outcome occurring given the
values of the marginal probabilities of each outcome and some
estimate of the correlation between the outcomes. The method is
limited to 2  2 tables, but there are many decision problems in
health technology assessment that fall into this class.
The examples demonstrate that multivariate predictions of
both, one, or neither outcome occurring can be sensitive to as-
sumptions about the correlation between outcomes. In the exam-
ple for adalimumab, the probability of achieving both a skin and
an arthritis response is 0.280 if these outcomes are assumed to be
independent, but 0.387 if the outcomes are assumed to be corre-
lated as observed from data from one of the RCTs.
The extent to which correlation between outcomes is important
for predictions of long-term effectiveness and cost-effectiveness in a
decision model depends on many other factors, such as whether
further treatment is offered or withdrawn depending on the initial
outcomes and the impact of each outcome on health-related quality
Table 5 – Data used for the illustrative decision problem: p
Parameter Valu
Odds ratio for skin response (adalimumab vs. placebo) 21
Odds ratio for arthritis response (adalimumab vs. placebo) 4
Probability of skin response with placebo 0.
Probability of arthritis response with placebo 0.
Probability of skin response with adalimumab 0.
Probability of arthritis response with adalimumab 0.
Phi correlation coefficient between arthritis and skin
responses with adalimumab
0.
Table 6 – Predicted contingent probabilities of skin and art
effectiveness of biologic therapy under different estimates
Expected probabilities of outcomes 12 weeks after adalimumab
Response to both
Arthritis response only
Skin response only
Neither response
Cost-effectiveness of adalimumab versus placebo, assuming
patients who do not respond for arthritis are withdrawn
from biologic therapy at 12 weeks
Incremental costs
Incremental QALY
ICER
Cost-effectiveness of adalimumab versus placebo, assuming
patients who do not respond for either skin or arthritis are
withdrawn from biologic therapy at 12 weeks
Incremental costs
Incremental QALY
ICER
In the adalimumab group, the expected marginal probability of an ar
a skin response is fixed at 0.477. In the no biologic therapy group, the
the expected marginal probability of a skin response is fixed at 0.044.
in the base-case model are shown in bold.
ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life-yeaof life and costs. The long-term implications of alternative assump-
tions about the correlation can be explored in sensitivity analysis by
varying the parameter within its lower and upper bounds and using
the corresponding contingentprobabilitieswithinadecisionanalytic
model. An illustrative example showed that the ICER of adalimumab
versus no biologic was about £18,500 per QALY if the responseswere
strongly positively correlated. The ICER increases to about £19,500
perQALY if the responses are independent. In this case, although the
total proportion of patients achieving an arthritis response (and
therefore continuing on adalimumab) is the same as the base case,
fewer patients will be expected obtain both a skin and arthritis re-
sponse if the responses are assumed to be independent. If the re-
sponses were strongly negatively correlated, the ICER could bemore
than£20,000perQALY.Althoughnegative correlationof outcomesat
12weeks is logically possible given the estimatedmarginal probabil-
ities of eachoutcome, it is probably clinically implausible in this case.
There are severalmeasures of association available for outcomes
in 2  2 tables. The phi coefficient is simple to calculate and widely
nown. However, the lower and upper bounds for the phi coefficient
ay be more restricted than [1,1] given the values of the marginal
bilities of response at 12 weeks.
ean (95% CI) Source of data
.13–74.56) Mease et al., 2005 [10]
.67–6.15) Univariate meta-analysis: Mease et al., 2005 [10];
Genovese et al., 2007 [20]
.028–0.065) Mean of placebo arm in Mease et al., 2005 [10]
.178–0.317) Weighted mean of placebo arms in Mease et al.,
2005 [10], Genovese et al., 2007 [20]
.275–0.693) Derived from probability of placebo response
and odds ratio (Rodgers et al., 2011 [8])
.444–0.713) Derived from probability of placebo response
and pooled odds ratio (Rodgers et al., 2011 [8])
.211–0.661) Rodgers et al., 2011 [8]
s responses to a biologic drug and estimates of cost-
e association between the responses.
Estimate of phi coefficient
0.878 0 0.436 0.801
0.064 0.280 0.387 0.477
0.523 0.307 0.200 0.110
0.413 0.197 0.090 0.000
0.000 0.216 0.323 0.413
£26,529 £25,665 £25,236 £24,877
1.206 1.314 1.368 1.413
£21,997 £19,532 £18,453 £17,612
£46,222 £34,059 £29,517 £24,877
1.413 1.413 1.413 1.413
£32,724 £24,820 £20,897 £17,612
s response is fixed at 0.587 and the expected marginal probability of
tedmarginal probability of an arthritis response is fixed at 0.249 and
ssumed responses are independent with no biologic therapy. Valuesroba
e m
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799V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 7 9 3 – 7 9 9probabilities. Therefore, if themeasureof associationavailable to the
analyst is the phi coefficient, then these bounds must be taken into
account when conducting univariate and probabilistic sensitivity
analyses. Themaximum andminimum values of othermeasures of
association such as Yule’s Q and Yule’s Y are independent of the
marginal probabilities. These alternativemeasures, however, do not
seem to be in common use in the medical literature.
It may be difficult to obtain any data to inform the correlation
betweenoutcomes for each treatment. In this case, theanalystmight
need to consider nonexperimental data sources and/or elicit expert
opinion. Data on the correlation between outcomesmay be available
for some but not all treatments. This was the case in a recent evalu-
ation of three biologic drugs, adalimumab, etanercept, and inflix-
imab [8],where thephi coefficientwas reportedbyone (adalimumab)
trial [10]. These data were not in the original trial publication and
werespeciallymadeavailableby themanufacturersof thedrug [8]. In
this case, it was assumed that the correlation coefficient between
skin andarthritis responses in the treatment armof the adalimumab
trial applied to all three biologic drugs under evaluation. This as-
sumption is difficult to validate without further data, and sensitivity
analyses were performed for different values. Alternatively, the cor-
relation for each treatment might be obtained from expert opinion,
althoughmethods to elicit these parameters would need to be care-
fully designed. One must be careful to distinguish between two dis-
tinct typesof correlation. Statisticalmethods for themeta-analysisof
multiple outcomes require data (or assumptions) on the correlations
or covariances between the treatment effects (as opposed to univar-
iatemeta-analysis, which only requires an estimate of themean and
variance of each treatment effect) [2,21–23]. In this article, rj refers a
different concept: the estimate of the correlation between two out-
comes or responses after a single treatment j.
The approach taken here is convenient and pragmatic. It has an
nalogy with solving a number puzzle like Sudoku. If the row and
olumn totals of a 2 2 table are known, there are logical bounds on
he four cell valueswithin the table. As themarginal probabilities are
ssumed fixed when calculating the internal cell probabilities, the
ethod is rather deterministic and should be considered a useful
xploratory measure [9,17]. Some test statistics such as the Fisher
xact test use a similar device, by computing the P value as if the
argins of the table were known exactly [24].
Because the marginals are estimated rather than known, that
hould introducemore uncertainty into the estimates of the internal
ell probabilities and the bounds. Ideally, all the parameters relevant
o the decision model would be estimated together to capture the
ependency among posterior correlations, variances, and means
hat are induced by their joint estimation from the data and propa-
ate these uncertainties forward into the decision model [9,22,25].
Despite its limitations, the simple and pragmatic method per-
its alternative assumptions about the correlation between out-
omes to be explored. Assuming that outcomes are independent
hen in fact they are correlated may bias the estimate of the ef-
ectiveness and cost-effectiveness of a therapy.
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